Trial Profile
Monitoring and Evaluation of the Therapeutic Efficacy and Safety of Pyronaridine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia, an Area of Artemisinin-resistant Falciparum Malaria
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Artesunate/pyronaridine (Primary)
- Indications Falciparum malaria
- Focus Therapeutic Use
- 18 Sep 2018 Status changed from recruiting to completed.
- 29 Feb 2016 Results published in the Antimicrobial Agents and Chemotherapy
- 22 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.